Recruiting Lung Cancer Studies in Kansas City
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ide...
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC...
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation....
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinu...
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve loc...
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer partici...
About Lung Cancer Clinical Trials in Kansas City
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 6 lung cancer clinical trials recruiting participants in Kansas City, KS. These studies are seeking a combined 1,207 participants. Research is being sponsored by Merck Sharp & Dohme LLC, University of Texas Southwestern Medical Center, Mirati Therapeutics Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Kansas City — FAQ
Are there lung cancer clinical trials in Kansas City?
Yes, there are 6 lung cancer clinical trials currently recruiting in Kansas City, KS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kansas City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.
Are clinical trials in Kansas City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 6 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov